| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A bold expressionist Brand of art therapy
|
Jenkins, Emily
|
|
2017
|
18 |
8 |
p. 1007-1008
|
artikel
|
| 2 |
All tumours are rare, but some are rarer than others
|
Munro, Alastair
|
|
2017
|
18 |
8 |
p. 983-985
|
artikel
|
| 3 |
A step towards predicting checkpoint inhibitor response in kidney cancer
|
Maia, Manuel Caitano
|
|
2017
|
18 |
8 |
p. 982-983
|
artikel
|
| 4 |
Atezolizumab in advanced non-small-cell lung cancer
|
Brower, Vicki
|
|
2017
|
18 |
8 |
p. e434
|
artikel
|
| 5 |
Bereaved and aggrieved in the age of social media
|
McNeil, Catriona M
|
|
2017
|
18 |
8 |
p. 1008
|
artikel
|
| 6 |
Beyond bad luck: induced mutations and hallmarks of cancer
|
Kelly-Irving, Michelle
|
|
2017
|
18 |
8 |
p. 999-1000
|
artikel
|
| 7 |
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
|
Gatta, Gemma
|
|
2017
|
18 |
8 |
p. 1022-1039
|
artikel
|
| 8 |
Calling time on the immunotherapy gold rush
|
The Lancet Oncology,
|
|
2017
|
18 |
8 |
p. 981
|
artikel
|
| 9 |
Cancer in the Renaissance court of Naples
|
Gaeta, Raffaele
|
|
2017
|
18 |
8 |
p. e432
|
artikel
|
| 10 |
Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
|
Levis, Bennett E
|
|
2017
|
18 |
8 |
p. e445-e456
|
artikel
|
| 11 |
Chilli—too hot to handle?
|
Craddock, Charles
|
|
2017
|
18 |
8 |
p. 1005
|
artikel
|
| 12 |
Colorectal adenomas, surveillance, and cancer
|
Løberg, Magnus
|
|
2017
|
18 |
8 |
p. e427
|
artikel
|
| 13 |
Colorectal adenomas, surveillance, and cancer – Authors' reply
|
Atkin, Wendy
|
|
2017
|
18 |
8 |
p. e428
|
artikel
|
| 14 |
Communicating cancer in the digital age
|
Lucas, Catherine
|
|
2017
|
18 |
8 |
p. 1006-1007
|
artikel
|
| 15 |
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
|
Faivre-Finn, Corinne
|
|
2017
|
18 |
8 |
p. 1116-1125
|
artikel
|
| 16 |
Correction to Lancet Oncol 2017; 18: 732–42
|
|
|
2017
|
18 |
8 |
p. e433
|
artikel
|
| 17 |
Correction to Lancet Oncol 2017; 18: 1022–39
|
|
|
2017
|
18 |
8 |
p. e433
|
artikel
|
| 18 |
Correction to Lancet Oncol 2017; 18: 917–28
|
|
|
2017
|
18 |
8 |
p. e433
|
artikel
|
| 19 |
Correction to Lancet Oncol 2017; 18: 1040–48
|
|
|
2017
|
18 |
8 |
p. e433
|
artikel
|
| 20 |
Correction to Lancet Oncol 2017; 18: 556–57
|
|
|
2017
|
18 |
8 |
p. e433
|
artikel
|
| 21 |
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
|
Tap, William D
|
|
2017
|
18 |
8 |
p. 1089-1103
|
artikel
|
| 22 |
Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial
|
Locatelli, Franco
|
|
2017
|
18 |
8 |
p. 1126-1136
|
artikel
|
| 23 |
Evidence-based management of adult patients with diffuse glioma – Authors' reply
|
Weller, Michael
|
|
2017
|
18 |
8 |
p. e430-e431
|
artikel
|
| 24 |
Evidenced-based medicine in glioma: molecular biology is only part of the story
|
|
|
2017
|
18 |
8 |
p. e429
|
artikel
|
| 25 |
FLT3 inhibition in acute myeloid leukaemia
|
Daver, Naval
|
|
2017
|
18 |
8 |
p. 988-989
|
artikel
|
| 26 |
Genomic approaches to accelerate cancer interception
|
Beane, Jennifer
|
|
2017
|
18 |
8 |
p. e494-e502
|
artikel
|
| 27 |
High-dose chemotherapy and autologous stem-cell transplantation for DLBCL in the rituximab era
|
Pfreundschuh, Michael
|
|
2017
|
18 |
8 |
p. 989-991
|
artikel
|
| 28 |
Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation
|
Lindner, Lars H
|
|
2017
|
18 |
8 |
p. 991-993
|
artikel
|
| 29 |
Increasing global access to cancer care: models of care with non-oncologists as primary providers
|
Rubagumya, Fidel
|
|
2017
|
18 |
8 |
p. 1000-1002
|
artikel
|
| 30 |
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
|
Turajlic, Samra
|
|
2017
|
18 |
8 |
p. 1009-1021
|
artikel
|
| 31 |
Leaving Cancer for the Circus
|
Denny, Victoria
|
|
2017
|
18 |
8 |
p. 1006
|
artikel
|
| 32 |
Low accuracy and reproducibility of melanoma diagnoses
|
Burki, Talha Khan
|
|
2017
|
18 |
8 |
p. e441
|
artikel
|
| 33 |
Midostaurin in FLT3-mutated acute myeloid leukaemia
|
Das, Manjulika
|
|
2017
|
18 |
8 |
p. e439
|
artikel
|
| 34 |
NCI oncologists excluded from some US insurance networks
|
Burki, Talha Khan
|
|
2017
|
18 |
8 |
p. e442
|
artikel
|
| 35 |
NICE recommends routine NHS funding for Kadcyla
|
Venkatesa, Priya
|
|
2017
|
18 |
8 |
p. e435
|
artikel
|
| 36 |
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|
Harrington, Kevin J
|
|
2017
|
18 |
8 |
p. 1104-1115
|
artikel
|
| 37 |
Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence
|
Kerr, Jacqueline
|
|
2017
|
18 |
8 |
p. e457-e471
|
artikel
|
| 38 |
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
|
Brown, Paul D
|
|
2017
|
18 |
8 |
p. 1049-1060
|
artikel
|
| 39 |
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial
|
Mahajan, Anita
|
|
2017
|
18 |
8 |
p. 1040-1048
|
artikel
|
| 40 |
Potential biomarker for acute myeloid leukaemia therapy
|
Gourd, Elizabeth
|
|
2017
|
18 |
8 |
p. e438
|
artikel
|
| 41 |
Potential drug targets in small-bowel adenocarcinoma
|
Gilbert, Judith A
|
|
2017
|
18 |
8 |
p. e436
|
artikel
|
| 42 |
Preventive therapy for cancer
|
Cuzick, Jack
|
|
2017
|
18 |
8 |
p. e472-e482
|
artikel
|
| 43 |
Prospective radiotherapy for patients with oropharyngeal carcinoma
|
Wang, Yue
|
|
2017
|
18 |
8 |
p. e425
|
artikel
|
| 44 |
Prospective radiotherapy for patients with oropharyngeal carcinoma – Authors' reply
|
Chen, Allen M
|
|
2017
|
18 |
8 |
p. e426
|
artikel
|
| 45 |
Quality of life after nivolumab treatment for head and neck cancer
|
Singer, Susanne
|
|
2017
|
18 |
8 |
p. 993-994
|
artikel
|
| 46 |
Questions over the import of radionuclides after Brexit
|
Baker, Holly
|
|
2017
|
18 |
8 |
p. e444
|
artikel
|
| 47 |
Rabbit anti-human-T-lymphocyte globulin—less is more
|
Boelens, Jaap Jan
|
|
2017
|
18 |
8 |
p. 996-997
|
artikel
|
| 48 |
Radiosurgery for resected brain metastases—a new standard of care?
|
Lo, Simon S
|
|
2017
|
18 |
8 |
p. 985-987
|
artikel
|
| 49 |
Risk prediction equations for survival in colorectal cancer
|
Burki, Talha Khan
|
|
2017
|
18 |
8 |
p. e437
|
artikel
|
| 50 |
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
|
Chiappella, Annalisa
|
|
2017
|
18 |
8 |
p. 1076-1088
|
artikel
|
| 51 |
Savolitinib for MET-driven papillary renal cell carcinoma
|
Gilbert, Judith A
|
|
2017
|
18 |
8 |
p. e440
|
artikel
|
| 52 |
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|
Perl, Alexander E
|
|
2017
|
18 |
8 |
p. 1061-1075
|
artikel
|
| 53 |
Some chemicals that cause tumours of the urinary tract in rodents
|
Grosse, Yann
|
|
2017
|
18 |
8 |
p. 1003-1004
|
artikel
|
| 54 |
TERT mutations in urine could predict bladder cancer recurrence
|
Gourd, Elizabeth
|
|
2017
|
18 |
8 |
p. e443
|
artikel
|
| 55 |
The role of government and regulation in cancer prevention
|
Brawley, Otis W
|
|
2017
|
18 |
8 |
p. e483-e493
|
artikel
|
| 56 |
The science of precision prevention of cancer
|
Vineis, Paolo
|
|
2017
|
18 |
8 |
p. 997-998
|
artikel
|
| 57 |
Tumour d'emblee
|
Razmi T, Muhammed
|
|
2017
|
18 |
8 |
p. e503
|
artikel
|
| 58 |
Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
|
Fietkau, Rainer
|
|
2017
|
18 |
8 |
p. 994-995
|
artikel
|
Tijdschrift beschrijving